“I’ve used adalimumab for patients with both widespread moderate-to-severe psoriasis as well as for those with milder regional specific disease (scalp, palms/soles and nails),” she notes. “With guselkumab, on the other hand, I’ve not chosen to use it yet solely for these three areas, but rather to treat patients with widespread psoriasis, some of whom are affected in these specified areas.”
“There are some limitations to this study, though,” she adds. “Since this is a post-hoc study, it may not be generalizable to people affected only in these specific areas (i.e., with milder disease) as opposed to patients with widespread psoriasis that also happens to include these regional areas, which reflects the patients that were initially enrolled in Voyage 1 and 2.”
“Also, the cleanest data in this study is limited to 24 weeks,” she says, “so data on the nails, which take longer to get better, may not reflect the complete picture.”
The study was funded by Janssen, which manufactures guselkumab. Dr. Blauvelt and three coauthors have received fees from Janssen and five coauthors are employees of the company.
Reference
- Foley P, Gordon K, Griffiths CEM, et al. Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: A secondary analysis of two randomized clinical trials. JAMA Dermatol. 2018 May 16. doi: 10.1001/jamadermatol.2018.0793. [Epub ahead of print]